Reference

The role of immunomodulatory drugs in multiple myeloma

The role of immunomodulatory drugs in multiple myeloma. Anderson, Kenneth C. (Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA). Seminars in Hematology, 40(4, Suppl. 4), 23-32 (English) 2003 W. B. Saunders Co. CODEN: SEHEA3. ISSN: 0037-1963. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A Review. Thalidomide has shown promise in the treatment of newly diagnosed multiple myeloma and relapsed/refractory disease, but side effects such as somnolence, constipation, and neuropathy limit its use. CC-5013, an immunomodulatory drug (IMiD), is more potent than thalidomide.In this article, certain chemicals are used. Some of their cas registry numbers are 50-35-1 and 191732-72-6 CC-5013 has various immunomodulatory effects, including growth arrest or apoptosis of drug-resistant myeloma cell lines and inhibition of binding of myeloma cells to bone marrow stromal cells. Clin., 17 of 24 patients (71%) with relapsed/refractory disease experienced a redn. of paraprotein of 3 25% following treatment with CC-5013, including 11 who had a history of treatment with thalidomide. Another two experienced stable disease. Median time to best response was 2 mo (range, 1 to 11) and median duration was 6 mo (range, 2 to 18). Grade 3 thrombocytopenia was seen in 20% of patients; grade 3 neutropenia was seen in 60%; and grade 4 neutropenia was seen in 16%. CC-5013 use was not assocd. with somnolence, constipation, or neuropathy. This article reviews thalidomide in multiple myeloma, the effects of thalidomide analogs IMiDs, and the preclin. and clin. data on CC-5013 in relapsed/refractory multiple myeloma. .

Lenalidomide for treatment of multiple myeloma

All Rights Reserved. Lenalidomide for treatment of multiple myeloma. 191732-72-6 is the cas registry number. This chemical is also mentioned in this article. Hattori, Yutaka (Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan). Ketsueki, Shuyoka, 52(4), 395-399 (Japanese) 2006 Kagaku Hyoronsha. CODEN: KETSBI. ISSN: 0915-8529. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review, discussing the chem., action mechanism and clin. pharmacol. of lenalidomide for treatment of multiple myeloma with regards to angiogenesis inhibition. .